Brain Natriuretic Peptide (BNP)
How the Test Works, What Levels Mean, & Clinical Uses 2026
BNP is a hormone your heart releases when it’s under pressure — and one of medicine’s most reliable tools for diagnosing heart failure at the bedside. A single blood draw, a 15-minute result, and a number below 100 pg/mL can effectively rule out heart failure as the cause of someone’s breathlessness. The test is straightforward. Interpreting it correctly is not — obesity, kidney disease, certain medications, and age all shift the numbers in ways that change the clinical picture entirely. This guide covers what BNP measures, what the numbers mean, and where the test can mislead you.
Key takeaways
- BNP is a 32-amino acid hormone released by the heart’s lower chambers (ventricles) when they’re stretched by excess pressure or blood volume. Elevated levels signal that the heart is working harder than normal.
- A BNP below 100 pg/mL effectively rules out acute heart failure as the cause of shortness of breath, with a negative predictive value above 90% — validated in the Breathing Not Properly Multinational Study (n=1,586).
- Patients taking sacubitril/valsartan (Entresto) must use NT-proBNP, not BNP, for monitoring. Sacubitril causes BNP to rise even as heart function improves, making BNP results misleading.
- Obesity reduces BNP levels by up to 50% in individuals with BMI above 35, potentially masking heart failure. Kidney disease and atrial fibrillation push BNP higher, independent of heart failure.
- Serial BNP measurements are more valuable than a single reading. A reduction greater than 30% from baseline correlates with improved cardiovascular outcomes.
Before you start BNP results should always be interpreted by a licensed healthcare provider alongside physical examination, imaging, and other laboratory findings. Never adjust heart failure medications based on a BNP number alone.
What is BNP?
BNP stands for brain natriuretic peptide is a name that has caused confusion ever since researchers discovered it comes primarily from the heart, not the brain. The “brain” label stuck because scientists first identified a similar peptide in brain tissue before the heart was recognized as its main source.
BNP is a 32-amino acid hormone released by the heart’s lower chambers (ventricles) when they’re stretched by too much blood volume or too much pressure. Think of it as your heart raising its hand to signal distress.
Once BNP enters the bloodstream, it triggers four responses that act as a natural counterbalance to fluid overload:
- Sodium excretion (natriuresis): BNP signals the kidneys to flush out sodium and water, reducing blood volume.
- Blood vessel relaxation (vasodilation): BNP dilates arteries and veins, lowering the pressure the heart pumps against.
- Aldosterone suppression: BNP reduces aldosterone, the hormone that tells kidneys to hold onto salt and water.
- Sympathetic nervous system dampening: BNP dials down fight-or-flight signals that speed up the heart and constrict blood vessels.
These four actions make BNP the body’s built-in defense against fluid overload. When heart failure develops and the ventricles struggle with excess volume, BNP production ramps up dramatically. That spike is what makes the blood test valuable: a higher BNP number means the heart is working harder than normal.
The ACC/AHA Heart Failure Guidelines assign BNP and NT-proBNP testing a Class I recommendation — the highest level of evidence-based endorsement — for diagnosing and risk-stratifying heart failure.
How BNP is produced in your heart
Understanding BNP’s origin explains why two related but different biomarkers exist — and why they behave so differently in clinical practice.
When the ventricular walls stretch from elevated filling pressures, valvular disease, or impaired heart function, heart muscle cells (cardiomyocytes) produce a precursor molecule called proBNP — a 108-amino acid protein.
Enzymes called corin and furin then cleave proBNP into two fragments:
- BNP (C-terminal fragment): 32 amino acids. The biologically active hormone that produces the natriuretic, vasodilatory, and neurohormonal effects above. Half-life: approximately 20 minutes.
- NT-proBNP (N-terminal fragment): 76 amino acids. Biologically inactive, but released in equal amounts alongside BNP. Half-life: approximately 120 minutes.
Both fragments enter the bloodstream in a 1:1 ratio. Because they come from the same precursor, both serve as biomarkers for the same underlying problem — ventricular wall stress. But their different sizes, half-lives, and clearance pathways mean they require different laboratory tests, have different reference ranges, and respond differently to certain medications.
When your doctor orders “a BNP test,” they are testing for one of these two fragments. Which one matters — and the next section explains why.
BNP vs NT-proBNP: what’s the difference?
BNP and NT-proBNP are not interchangeable. Choosing the right test depends on your medications, your age, and the clinical question being asked.
| Factor | BNP | NT-proBNP |
|---|---|---|
| What it is | Active 32-amino acid hormone | Inactive 76-amino acid fragment |
| Half-life | ~20 minutes | ~120 minutes (6x longer) |
| Acute heart failure rule-out cutoff | <100 pg/mL | <300 pg/mL |
| Chronic heart failure threshold | 35–100 pg/mL (varies by lab) | 125 pg/mL (age-adjusted; see below) |
| Significantly affected by age? | Mild increase | Yes — age-adjusted cutoffs required |
| Cleared by kidneys? | Partially | More kidney-dependent |
| Compatible with sacubitril/valsartan (Entresto)? | No — paradoxical elevation | Yes — falls appropriately with therapy |
| Point-of-care bedside testing? | Yes (15-minute turnaround) | Some assays available; lab testing more common |
The sacubitril/valsartan issue — this matters
Sacubitril/valsartan (Entresto) is a standard heart failure medication validated in the PARADIGM-HF trial. Sacubitril works by inhibiting an enzyme called neprilysin. Neprilysin normally degrades BNP in the bloodstream.
When you take sacubitril/valsartan, BNP accumulates rather than being cleared — levels rise even when heart function is improving. This creates a dangerous paradox: your BNP looks worse while you’re actually getting better.
NT-proBNP is not degraded by neprilysin. Its levels fall appropriately as heart failure therapy takes effect.
Important: If you take sacubitril/valsartan (Entresto), your doctor should track NT-proBNP rather than BNP. Using BNP to monitor therapy in these individuals leads to misinterpretation.
Age-adjusted NT-proBNP cutoffs
NT-proBNP levels naturally rise with age. The ICON study established age-stratified cutoffs for ruling in heart failure:
- Under 50 years: 450 pg/mL
- 50–75 years: 900 pg/mL
- Over 75 years: 1,800 pg/mL
The rule-out threshold of 300 pg/mL applies across all age groups.
How BNP tests diagnose heart failure
BNP’s greatest clinical strength is ruling out heart failure in patients who arrive at the emergency department with acute shortness of breath (dyspnea). Shortness of breath has many causes — heart failure, COPD, pulmonary embolism, pneumonia, anxiety. BNP helps narrow the diagnosis quickly.
Key takeaways
- A BNP below 100 pg/mL rules out heart failure with greater than 90% negative predictive value (Breathing Not Properly Multinational Study, n=1,586).
- Gray zone results (100–500 pg/mL) require echocardiogram, clinical examination, and repeat testing — not a definitive diagnosis.
- BNP above 500 pg/mL carries approximately 90% positive predictive value for heart failure.
- Adding BNP to standard clinical judgment increased diagnostic accuracy from 74% to 81.5% in the Breathing Not Properly Study.
The three-zone interpretation framework
| BNP level | What it means | What happens next |
|---|---|---|
| Below 100 pg/mL | Heart failure is very unlikely as the cause of symptoms (negative predictive value >90%) | Pursue other diagnoses: COPD, pulmonary embolism, pneumonia, anxiety |
| 100–500 pg/mL (gray zone) | Heart failure is possible but not confirmed; other conditions may be contributing | Repeat BNP in 2–4 weeks; get an echocardiogram; evaluate clinical signs; assess confounders |
| Above 500 pg/mL | Heart failure is highly likely (positive predictive value ~90%) | Begin or intensify heart failure treatment; echocardiogram; cardiology referral |
The Breathing Not Properly Multinational Study (McCullough et al., Circulation, 2002) validated these thresholds in 1,586 patients presenting with acute dyspnea across 7 medical centers. At the 100 pg/mL cutoff, BNP showed 90% sensitivity and 73% specificity for heart failure diagnosis.
Point-of-care testing: results in 15 minutes
Point-of-care BNP immunoassays deliver results at the bedside within 15 minutes. This speed is critical in emergency settings — distinguishing heart failure from other causes of breathing difficulty directly affects which treatment begins first. Laboratory assays offer broader measurement ranges for chronic monitoring but take several hours to return.
Navigating the gray zone (100–500 pg/mL)
Gray zone results are common and require additional evaluation rather than a definitive call. The recommended approach:
- Repeat BNP in 2–4 weeks to check whether levels are trending up or down
- Get an echocardiogram to assess directly how well the heart is pumping and filling
- Evaluate clinical signs: jugular vein distension, lung crackles, chest X-ray for pulmonary congestion, leg swelling
- Check for confounders: Is the individual obese (BNP may be falsely low)? Is there kidney disease (BNP may be falsely high)? Is atrial fibrillation present?
What affects BNP accuracy: obesity, kidney disease and other confounders
BNP is not a perfect mirror of heart function. Several conditions push BNP up or down independent of heart failure status.
Key takeaways
- Obesity reduces BNP by approximately 50% in individuals with BMI above 35, potentially masking heart failure — a lower cutoff (~50 pg/mL) may be appropriate.
- Kidney disease can elevate BNP two to three times above expected, making elevated levels less specific for heart failure.
- Atrial fibrillation raises BNP by 20–50% independent of heart failure; BNP specificity drops from ~0.9 in sinus rhythm to ~0.7 in atrial fibrillation.
| Confounder | Effect on BNP | Approximate magnitude | Why it happens | Clinical impact |
|---|---|---|---|---|
| Obesity (BMI >30) | Lowers BNP | ~30% reduction (BMI 30–35); ~50% reduction (BMI >35) | Adipose tissue expresses natriuretic peptide clearance receptors (NPR-C) that pull BNP out of the bloodstream faster | Heart failure can be masked. Consider lower cutoff (~50 pg/mL) for BMI >35. |
| Kidney disease (GFR <60) | Raises BNP | 2–3x higher than expected | Reduced renal clearance allows BNP to accumulate. NT-proBNP is more kidney-dependent than BNP. | Elevated BNP may not indicate heart failure in CKD. Clinical correlation with echo and exam is essential. |
| Atrial fibrillation | Raises BNP | 20–50% above baseline, independent of heart failure | Atrial stretch from irregular rhythm triggers natriuretic peptide release from both atria and ventricles | Specificity drops from ~0.9 (sinus rhythm) to ~0.7 (atrial fibrillation). Most AF patients with BNP >100 pg/mL do have heart failure. |
| Age | Raises BNP (especially NT-proBNP) | Gradual increase with advancing age | Age-related cardiac stiffening and reduced renal clearance | Use age-adjusted NT-proBNP thresholds. BNP is less affected by age than NT-proBNP. |
| Female sex | Slightly higher BNP | Modest increase compared to males | Hormonal and body composition differences | Minor clinical impact; most cutoffs are not sex-adjusted |
The obesity problem: hidden heart failure
The obesity confounder deserves specific attention. A 2005 study found that 20% of acutely decompensated heart failure patients with BMI ≥30 had BNP values below 100 pg/mL — the standard rule-out threshold. BNP decreased approximately 3% for every 1-unit increase in BMI.
For individuals with BMI above 35, a lower BNP cutoff of approximately 50 pg/mL may be more appropriate. If clinical suspicion for heart failure is high but BNP is lower than expected, obesity should be considered as a masking factor before ruling heart failure out.
Serial BNP monitoring: why trends matter more than single values
A single BNP reading tells you where things stand right now. Serial measurements over time tell you whether things are getting better, getting worse, or holding steady. For heart failure management, the trend is more informative than any individual number.
Recommended monitoring protocol
| Timepoint | Action | Target |
|---|---|---|
| Baseline | Obtain BNP before starting or adjusting therapy | Establishes personal reference point |
| 4 weeks | Retest to assess initial treatment response | Consider increasing diuretic dose or advancing therapy if BNP dropped <20% |
| 12 weeks | Optimization checkpoint | A >30% reduction from baseline correlates with improved cardiovascular outcomes |
| Ongoing | Retest with any symptom change, medication adjustment, or hospitalization | — |
What the trends mean
- BNP drops >30% from baseline: Therapy is working. Continue current regimen; monitor at routine intervals.
- BNP drops 20–30% from baseline: Partial response. Consider intensifying therapy or evaluating adherence.
- BNP drops <20% or rises: Poor response. Re-evaluate diagnosis, medication doses, fluid and salt intake, and adherence. Consider specialist referral.
Medication-specific monitoring notes
Sacubitril/valsartan (Entresto): Switch to NT-proBNP monitoring at initiation. BNP will rise due to neprilysin inhibition regardless of clinical improvement.
Diuretics: BNP should fall within days of effective diuresis as volume overload decreases.
Beta-blockers: BNP may initially rise slightly during titration before falling with long-term therapy. This is an expected pattern, not a sign of worsening.
BNP for prognosis and risk prediction
BNP does more than diagnose heart failure. Elevated levels independently predict adverse cardiovascular outcomes even after accounting for other risk factors like ejection fraction, age, and other conditions.
Heart failure prognosis
Higher BNP levels at discharge after a heart failure hospitalization predict higher rates of rehospitalization and death within 90 days. The REDHOT study (Rapid Emergency Department Heart Failure Outpatient Trial) confirmed BNP as a strong predictor of 90-day cardiac mortality and subsequent emergency visits. Serial BNP reductions during therapy correlate with improved long-term survival.
Sepsis mortality prediction
BNP and NT-proBNP rise in sepsis through inflammatory cytokine-mediated cardiac stress. NT-proBNP levels above 1,400 pmol/L in sepsis independently predict mortality. This makes natriuretic peptide testing useful for risk stratification even outside the heart failure context.
After a heart attack
After a myocardial infarction, elevated BNP identifies individuals at higher risk for developing subsequent heart failure and death. BNP measurement post-MI can guide the aggressiveness of follow-up monitoring and therapy decisions.
Heart failure with preserved vs reduced ejection fraction
BNP levels are typically higher in heart failure with reduced ejection fraction (HFrEF) than in heart failure with preserved ejection fraction (HFpEF). Both forms retain prognostic value from BNP monitoring — individuals with HFpEF and elevated BNP have worse outcomes than those with normal BNP levels, even though absolute values tend to be lower.
Other conditions that raise BNP
An elevated BNP does not automatically mean heart failure. Several conditions cause BNP to rise through mechanisms unrelated to left ventricular dysfunction.
Pulmonary embolism: Blood clots in the lungs cause acute right ventricular strain, which triggers BNP release. BNP elevation in pulmonary embolism indicates right heart involvement and is associated with worse prognosis.
Sepsis and severe infections: Inflammatory cytokines directly stimulate BNP release from cardiomyocytes. Levels above 1,000 pg/mL can occur in sepsis without primary heart failure.
COPD with cor pulmonale: Chronic lung disease causing right-sided heart strain elevates BNP from right ventricular wall stress. Pulmonary function tests and echocardiography help distinguish COPD-related elevation from left-sided heart failure.
Cardiac surgery: BNP rises transiently after open-heart procedures from perioperative myocardial stress. Levels typically normalize within weeks.
Acute coronary syndrome: Myocardial injury and ischemia trigger BNP release even without established heart failure.
Pulmonary hypertension: Elevated pulmonary artery pressures cause right ventricular strain — the same mechanism as left-sided failure, from the other direction.
Important: BNP should never be interpreted in isolation. Your physician combines the BNP result with physical examination, chest X-ray, echocardiogram, troponin levels, D-dimer, and other tests to reach an accurate diagnosis.
How the BNP blood test is performed
The BNP test is a straightforward blood draw with no special preparation required.
- Sample collection: Standard venipuncture (arm vein blood draw) into an EDTA tube (purple-top tube)
- Fasting: Not required — BNP can be drawn at any time of day regardless of meals
- Point-of-care testing: Bedside immunoassays deliver results within 15 minutes, common in emergency departments
- Laboratory testing: Broader measurement ranges and higher precision; results typically take 1–4 hours
- Sample stability: EDTA-plasma BNP levels decrease significantly after 4 hours at room temperature — samples should be processed promptly
- Cost: BNP and NT-proBNP tests typically cost $30–$150 depending on facility and insurance coverage; most insurance plans cover BNP when ordered for a clinical indication
Clinical guidelines and recommendations
BNP and NT-proBNP testing carries the strongest possible endorsement from major cardiology bodies.
ACC/AHA Heart Failure Guidelines: Class I recommendation — the highest evidence-based endorsement — for using BNP or NT-proBNP in the diagnosis and risk stratification of heart failure. Class I means the benefits of testing substantially outweigh the risks, supported by strong evidence from multiple studies.
Heart Failure Society of America (HFSA): Recommends measuring BNP when the diagnosis of heart failure is uncertain; endorses serial monitoring for therapy guidance.
European Society of Cardiology (ESC): Recommends a BNP below 100 pg/mL or NT-proBNP below 300 pg/mL to rule out heart failure in untreated patients with acute symptoms.
FDA regulation: BNP immunoassays are regulated as in vitro diagnostic devices requiring 510(k) clearance. Both point-of-care and laboratory assays have met FDA standards for diagnostic accuracy.
When to ask for a cardiology referral: Unexplained shortness of breath, newly diagnosed heart failure, a gray-zone BNP result (100–500 pg/mL), or rising BNP despite treatment all warrant a comprehensive evaluation including echocardiography.
The bottom line
BNP is one of medicine’s most reliable bedside biomarkers — a hormone your heart releases under stress that doubles as a rapid diagnostic tool. A number below 100 pg/mL effectively rules out acute heart failure as the cause of breathlessness, while a greater than 30% reduction from baseline signals that your treatment is working. The test is only as useful as the context around it, though: if you’re obese, have kidney disease, take sacubitril/valsartan, or have atrial fibrillation, a raw BNP number tells an incomplete story. Talk with your doctor about whether BNP or NT-proBNP is the right test for your situation, whether serial monitoring makes sense given your medications, and which confounders may be shifting your results.
Frequently Asked Questions
When should I have NT-proBNP tested instead of BNP?
NT-proBNP is the better choice in three situations. First, if you take sacubitril/valsartan (Entresto) — this medication causes BNP to rise while NT-proBNP falls appropriately with improving heart function. Second, for chronic heart failure monitoring, where NT-proBNP’s longer half-life (120 minutes vs 20 minutes) provides more stable readings. Third, for individuals over 50, where age-adjusted NT-proBNP cutoffs improve diagnostic accuracy.
Can COPD cause elevated BNP without heart failure?
Yes. COPD with cor pulmonale — right-sided heart strain from chronic lung disease — elevates BNP independent of left ventricular failure. The right ventricle stretches from elevated pulmonary pressures, triggering BNP release through the same wall-stress mechanism as left-sided failure. Pulmonary function tests and echocardiography help distinguish COPD-related elevation from primary heart failure.
Does obesity affect BNP test accuracy?
Yes, significantly. Obesity reduces circulating BNP by approximately 30% in individuals with BMI 30–35 and by approximately 50% in those with BMI above 35. Adipose tissue expresses natriuretic peptide clearance receptors (NPR-C) that pull BNP out of the bloodstream faster. Heart failure can be missed in individuals with obesity if standard cutoffs are applied without adjustment. A lower threshold of approximately 50 pg/mL may be more appropriate for BMI above 35.
What does a gray zone BNP result (100–500 pg/mL) mean?
A gray zone result means heart failure is possible but not confirmed. Recommended next steps: repeat BNP in 2–4 weeks to assess the trend, get an echocardiogram to evaluate heart function directly, assess clinical signs (neck vein distension, lung sounds, leg swelling, chest X-ray), and check whether obesity, kidney disease, or atrial fibrillation may be influencing the result.
How often should BNP be retested after starting heart failure medications?
The recommended protocol: baseline before starting therapy, retest at 4 weeks to assess initial response, then again at 12 weeks for an optimization checkpoint. Target a greater than 30% reduction from baseline. Retest sooner if symptoms worsen or medications change. If you take sacubitril/valsartan, switch to NT-proBNP rather than BNP for all ongoing monitoring.
Is BNP the same as atrial natriuretic peptide (ANP)?
No. BNP and ANP are both natriuretic peptides, but they come from different parts of the heart. ANP is secreted primarily by atrial (upper chamber) cardiomyocytes. BNP is secreted primarily by ventricular (lower chamber) cardiomyocytes. BNP is the preferred clinical biomarker for heart failure because ventricular dysfunction is the hallmark of most heart failure — making ventricular-derived BNP a more specific indicator.
Can BNP levels be normal even with heart failure?
Yes, in specific circumstances. Obesity is the most common reason: individuals with BMI above 35 can have heart failure with BNP levels below the standard 100 pg/mL cutoff. Very early or mild heart failure may also produce only modest BNP elevation. This is why BNP should be interpreted alongside clinical examination and echocardiography rather than used as the sole diagnostic tool.
Concerned about a BNP result or managing heart failure therapy? A licensed cardiologist or heart failure specialist can review your labs in the context of your complete clinical picture and help determine whether your current monitoring approach is appropriate.
References
McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416–422. PMID: 12135939
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161–167. (Breathing Not Properly Study primary publication)
Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1,256 patients (ICON study). Eur Heart J. 2006;27(3):330–337.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895–e1032.
McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993–1004.
Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715–731.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. BNP and NT-proBNP test results should always be interpreted by a licensed healthcare provider in the context of your complete clinical picture, including physical examination, imaging, and other laboratory findings. PeptideRx does not provide medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before making any decisions about cardiac testing or heart failure management.